A Case-Based Roadmap for Improved Patient Outcomes in Psoriatic Arthritis

To participate in this activity, please:

Patients with psoriatic arthritis (PsA) experience significant disease burden due to incomplete diagnostic evaluation and suboptimal use of effective therapies. In this case-based activity, Dr. Leonard Calabrese of the Cleveland Clinic addresses these practice gaps by sharing his recommendations for patient management at critical decision points in the diagnosis and treatment of patients with PsA. Dr. Calabrese also discusses the important role of shared decision-making over the course of the disease as a key strategy to individualize treatment and improve patient adherence. For each of the 3 cases, Dr. Calabrese provides a concise summary of key concepts to facilitate integration into clinical practice.

Course Credit:

0.75 AMA PRA Category 1 CreditTM


Opens: 2021-01-22
Closes: 2022-01-22

Target Audience:

This activity is intended for a national audience of rheumatologists, dermatologists, primary care physicians, nurse practitioners, physician assistants, and other healthcare providers who manage patients with psoriatic arthritis.

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
  • Leonard Calabrese, DO

    Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Director, RJ Fasenmyer Center for Clinical Immunology
    Cleveland Clinic
    Cleveland, Ohio

Learning Objectives

  • Utilize validated tools to assess Psoriatic Arthritis (PsA) disease burden and response to treatment
  • Summarize the clinical pharmacology, including mechanism of action, as well as safety and efficacy, of evidence-based medications for PsA
  • Utilize a treat-to-target approach with individualized evidence-based therapy to achieve disease remission/low disease activity and reduce symptom burden
  • Individualize treatment of PsA based on treatment history and comorbidities

Faculty Disclosures

Leonard Calabrese, DO

Consultant: AbbVie, Amgen, BMS, Crescendo, Eli Lilly, Genentech, Gilead, GSK, Horizon, Jansen, Kiniksa, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB

Speakers Bureau: AbbVie, BMS, Genentech, Novartis, Regeneron, Sanofi-Genzyme

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.